Analyst Jill Wu of CMB International Securities maintained a Buy rating on QuantumPharm, Inc. (2228 – Research Report), with a price target of HK$7.57.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Jill Wu’s rating is based on QuantumPharm, Inc.’s robust growth prospects and strategic partnerships. The company leverages its AI-driven R&D platform to achieve stable revenue growth, particularly in drug discovery and intelligent automation solutions. These solutions not only enhance the efficiency of the drug development process but also expand into new materials and energy fields, indicating a strong growth trajectory.
QuantumPharm’s extensive network of partnerships further underscores its potential across various industries. Collaborations with leading pharmaceutical firms and other sectors, such as new energy materials and traditional Chinese medicine, highlight its broad commercial prospects. Additionally, the company’s recent fundraising efforts have strengthened its financial position, supporting future growth initiatives. These factors collectively position QuantumPharm for continued success, justifying the Buy rating.
2228’s price has also changed dramatically for the past six months – from HK$13.040 to HK$6.760, which is a -48.16% drop .